Fondazione Telethon and Orchard Therapeutics complete transfer of marketing authorization of Strimvelis for ADA-SCID in Europe

01 / 01

Fondazione Telethon will now be responsible for providing the gene therapy to eligible patients in the European Union.

On the eve of the 26th World Rare Disease Day, Fondazione Telethon announces its commitment to ensure that gene therapy for Wiskott-Aldrich syndrome (WAS), a rare genetic disease of the immune system, will be available in the next future.

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.